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ABSTRACT 
Breast cancer is one of the most prevalent female cancers found in Western 
countries. Southeast Asian women have a lower incidence of breast cancer compared 
to their counterparts in Western countries, and the difference in soy consumption has 
been claimed to be the major contributing factor. 
The antiestrogen tamoxifen has been prescribed to patients as a part of breast 
cancer treatment. However, it exerts some serious adverse side effects to patients if 
administration of tamoxifen is longer than 2 years. Genistein is a flavonoid and the 
most extensively studied phytochemical in soy. It is commonly accepted as a breast 
cancer preventive agent and its proposed antiestrogenic property is believed to play a 
crucial part in its chemopreventive mechanism. 
In view of the similarity in structure, many chemicals found in Chinese 
medicine may have comparable properties to genistein. The estrogenic and 
antiestrogenic properties of these phytochemicals were examined, and their potential 
to be used as a natural alternative to specific estrogen receptor modulator (SERM) 
was explored. After a series of screening, baicalein was identified as a candidate of 
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antiestrogen. It is a flavonoid found in the root of Scutellaria baicalensis Georgi, and 
is widely used as health supplement and herbal medicine in Asian countries. The 
preliminary studies showed that the antiestrogenic activity of baicalein was more 
promising than genistein. 
In this study a transient transfection model was used to investigate the pro- and 
antiestrogenic effect of flavones including baicalein and flavone, flavonols (quercetin, 
kaempferol) and isoflavones (genistein, biochanin A). Among the tested flavonoids, 
baicalein was the strongest competitor to 17p-estradiol for estrogen receptor binding. 
Transient transfection results indicated that baicalein concentration as low as 10'^  M 
could significantly suppress 17P-estradiol-induced transactivation in cells expressing 
either estrogen receptors a or p. By using cell free estrogen-R (a) competition assay, 
IC50 of these compounds were compared in view of receptor levels. Similar result 
was obtained. Baicalein was found to be the strongest antiestrogen with IC5016 [iM. 
Baicalein was also the strongest cell death-inducing agent to the estrogen 
receptor-positive MCF-7 breast cancer cell line; whereas all phytochemicals 
exhibited comparable magnitude in the induced death of the estrogen 
receptor-negative breast cancer cells MDA-MB-231. The difference of apoptotic 
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index in the estrogen receptor-positive (MCF-7) and estrogen receptor-negative 
(MDA-MB-231) cancer cell lines suggested mechanism causing cell death was partly 
dependent on the presence of estrogen receptor. 
Current focus would be on the death-related gene expression affected by the 
activation or deactivation of estrogen receptor. Therefore, RT-PCR was carried out to 
determine the Bcl2/ Bax mRNA expression level after treatment of both cell lines 
with different concentrations of these compounds. Unlike genistein and others, the 
fact that baicalein failed to increase Bcl-2 expression might contribute to the 
induction of MCF-7 cell death at a lower concentration. Furthermore, Baicalein 
could reduce intracellular triglyceride and cholesterol in HepG2 cells compared with 
that of genistein. In conclusions, baicalein could be a better natural alternative for the 














系列的歸選，黃夸黃素（Baica l e in )被認爲是一種抗雌激素物。他是在 







豆芽素A (Biochanin A)在內的黃酮累的抗雌激素效果。在被檢測的黃酮類化 
合物當中，黃萼黃素是np—雌二醇（Estradiol)最強的雌激素受體結合競爭 
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CHAPTER 1 GENERAL INTRODUCTION 
Breast cancer is one of the most common cancers in women. Women in Asian 
countries with high soy consumption suffering from post-menopausal diseases, such 
as osteoporosis, cardiovascular disease, breast and endometrial cancers, are less than 
their counterparts in the West (Ingram et al. 1997; Goodman et al. 1997; Tham et al. 
1998; Davis et al. 1999). Epidemiological studies have demonstrated that high 
phytoestrogen consumption is associated with low incidence of breast cancer 
(Ingram et al. 1997)，and women with high risk of breast cancer are advised to take 
phytoestrogen to control the postmenopausal symptoms as well as to minimize their 
cancer risks (Lee et al. 2000). In an intervention study, it has shown that the 
consumption of isoflavone-rich soy protein can reduce bone loss in the lumbar spine 
of perimenopausal women (Alekel et al. 2000). This soy protein effect on lumbar 
spine can also be seen in postmenopausal women in Japan (Horiuchi et al. 2000). In 
an animal model experiment, soy protects bone loss (Arjmandi et al. 1996; Picherit et 
al. 2000) and mammary tumors (Barnes et al. 1998; Lamartiniere et al. 1998). 
18 
1.1 Estrogen and Estrogen Receptors and its Action 
1.1.1 Estrogen 
Estrogen is a hormone that is essential for the normal growth of the breast and 
tissues important for reproduction. It is important for childbearing and helps regulate 
a woman's menstrual cycles. It also helps maintain healthy bones and the heart. 
However, lifetime exposure to estrogen is also associated with increasing a woman's 
risk for breast cancer. Understanding how estrogen works in the body may help 




Figure 1.1 Structure of 17p-estradioL 
1.1.2 Estrogen Receptors 
Recent studies have revealed the existence of two distinct estrogen receptors in 
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our bodies: ERa and ERp. While they both bind estrogen as well as other agonists 
and antagonists, the two receptors have distinctly different localizations and 
concentrations within our body. Structural differences also exist between the two 
allowing for a wide range of diverse and complex processes to take place. The 
following diagram, adopted from the Gustafsson review (1999), shows the 
distribution of ERa and ERp. 
Cemrai nefvo^ s ERp 
、 函 
BfCMiERaERp Cardiovascular 
system: ERa ERp 
L A f l u A Gastromtestmal 
ERp 
( U r o g e n i t a l iraa: 
(I R ^ O T 丨 擊 P 
； 
Bone; ERa. ERp \ 
1 
Figure 1.2 Distribution of ERa and ERp in human 
(Adopted from the Gustafsson review 1999) 
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1.1.3 Structural Differences between ERa and ERp 
Two of the most interesting sites on the ER molecule are its ligand binding 
domain (LBD), otherwise known as AF-2, and its growth factor binding domain, 
otherwise known as AF-l. In addition, the DNA-binding domain (DBD) is 
responsible for binding at estrogen response elements (ERE) on the chromosome. A 
subtle difference between the two in their ligand-binding pockets is the substitution 
of Leucine 338 in ERa with Methionine 384 in ERp. The following diagram, adopted 
from the Gustafsson review (1999)，compares the amino acid sequences of the two 
receptors: 
1 1S5 251 355 549 595 
NHD OBE Hinge LBD F H E R O T 
: 4 5 148 214 304 500 530 
16 97 30 59 18 h E R § 
The separate domains are identified in the ERa diagram; the numbers in the 
ERp diagram show the sequence identity as %. 
Figure 1.3 Amino acid sequences of two receptor ER a and p. 
(Adopted from the Gustafsson review 1999) 
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1.1.4 Functional Differences 
Interestingly, ERa and ERp, when complexed with estrogen, were shown to 
signal in opposite ways from an API site, with estrogen activating transcription in 
the presence of ERa and inhibiting transcription in the presence of ERp. The ER 
ligands tamoxifen, raloxifene, and ICI-164384 were activators with ERp as well as 
ERa, although the degree of agonism differed between cell types. These molecules 
are examples of SERM's, selective estrogen receptor modulators. Thus, the role of 
estrogen complexed to ERp appears to be to turn off transcription of these genes, 
whereas the SERMs may override this blockade and activate gene transcription. 
1.1.5 Effects of Selective Estrogen Receptor Modulators 
Most recent drugs targeted to the ER, such as tamoxifen, ICI-164384, and 
raloxifene act as either ER antagonists or agonists depending on the species, tissue, 
and the dose administered. For instance, raloxifene has been reported to act as an 
antiestrogen in breast tumor tissue and the brain, while it has potentially beneficial 
estrogen-like effects in bone and in modulating factors associated with 
cardio-vascular diseases. Another example is tamoxifen, which was developed as an 
antiestrogen for the treatment of breast cancer and was subsequently shown to have 
estrogen-like effects on bone and the cardiovascular system (Ingram et al. 1997; 
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Goodman et al. 1997; Tham et al. 1998; Davis et al. 1999). However, the potentially 
beneficial effects of tamoxifen in reducing the risk of osteoporotic fractures and 
coronary heart disease in postmenopausal women are at least partially offset by its 
estrogenic effects on the uterus, increasing risk of endometrial cancer development. 
1.1.6 Estrogen works 
Estradiol (E) binds with high affinity to estrogen receptor (ER). The E-ER 
complex homodimerizes and localizes preferentially in the cell nucleus. And, the 
E-ER homodimer binds DNA sequence at palindromic estrogen response element 
(ERE) in the promoter region of estrogen-sensitive genes. Activation of transcription 
by ER involves interaction of ER, AFl and AF2 with transcription coactivators to 
stimulate the activity of RNA polymerase 11. The following diagram (Howell et al. 
2000) shows the mechanism action of estradiol. 
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Figure 1.4 Mechanism of action of estradiol. 
(Adopted from the Howell et al. 2000) 
1.1.7 Estrogen Receptors and Breast Cancer 
The sex hormone estrogen is important for many physiological processes, 
including growth, differentiation, and function of reproductive tissues (Osborne et al. 
2000) but prolonged stimulation of breast ductal epithelium by estrogen can 
contribute to breast cancer. When it was discovered that nearly all of the effects of 
estrogens, including breast cancer, are mediated through their binding to nuclear 
proteins called estrogen receptors (ER), it brought about a revolution in breast cancer 
biology and therapy. Research revealed that other natural compounds and synthetic 
drugs are also capable of binding to the estrogen receptor and that some can be used 
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to treat breast cancer. It is now known that many breast cancers are 
estrogen-dependent and will respond to various hormonal therapies (Howell et al. 
2000). 
1.2 FLAVONOIDS： PROPERTIES AND BIOLOGICAL ACTIVITIES 
1.2.1 Chemical Structure and Classification of flavonoids 
Flavonoids are diphenolic compounds which are present in high concentrations 
in whole grains, legumes, fruits and vegetables, some of which are consumed 
everyday. Flavonoids, either natural or synthetic, are well known to exhibit various 
biological activities. They are structurally similar to estrogens and are able to bind to 
the estrogen receptor and possess estrogenic or antiestrogenic activities. Figure 1.6 
shows the chemical structures of flavonoids used in this study. 
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R4' 
V Y Y ^^YVV^ 
R8 K A . R8 
FV 
Rs 
Flavone and flavonol Isoflavone 
Substituents at positions 
R3 R3， R4' Rs R6 R? Rg 
Flavones 
Baicalein OH OH OH 
Flavonols 
Kaempferol OH OH OH OH 
Quercetin OH OH OH OH OH 
Isoflavones 
Genistein OH OH OH 
Biochanin A OCH3 OH OH 
Figure 1.5 Chemical structures of flavonoids used. 
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1.2.2 Biological Properties and Action Mechanism of Flavonoids 
Since flavonoids are abundant in food and medical plants used in folk medicine， 
so the pharmacological and biological actions of flavonoids have extensively studied. 
Many of them are potent anti-oxidants, anti-inflammatory, anti-allergic, anti-viral, 
anti-toxic, hepatoprotective and enzyme-inhibiting substrates (Middleton and 
Kandaswami 1993). 
The flavonoids in soybeans occur as conjugates. When consumed, they undergo 
metabolic conversions in the gut whereby the sugar molecule is removed, and 
conversion to metabolically active aglycons occurs. After this conversion, 
approximately one third of the aglycon is absorbed as free isoflavone, and two thirds 
undergo further metabolism by the intestinal microflora and are converted to 
isoflavone metabolites such as equol and />-ethylphenol, which are then absorbed. 
Both intact and metabolized isoflavones freely circulate in the blood and are excreted 
in the urine within 24 hours (Vincent et al. 2000). 
1.2.3 Flavonoids and breast cancer prevention 
In Japan, the usual diet is rich in soy protein, and Japanese women enjoy one of 
the lowest rates of breast cancer in the world. Japanese immigrants to the United States 
who adopt a Western diet have rates of breast cancer comparable to those of American 
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women. These epidemiological studies have led to the belief that soy-containing diets 
confer some protection against this condition. Other researchers suggest that the 
higher fat content in the typical American diet is responsible for the differences in the 
rate of breast cancer (Henderson M. 1995). Thus, epidemiological studies do not 
provide a definitive answer regarding the ability of soy to protect against breast 
carcinoma. Work in our laboratory suggests a protective effect of soy protein on breast 
tissue. Animal studies indicate that soy supplementation resulted in inhibition of 
chemical- and radiation-induced breast tumors in rodents (Troll at al. 1980). 
I 
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1.3 AIMS AND SCOPES OF INVESTIGATION 
Flavonoids are a broadly distributed class of naturally occurring phenolic 
compounds found in a wide variety of plants, including most common fruits and 
vegetables. They are widely used in traditional medicine and as food supplements. 
Although the importance of flavonoids is becoming more prominent in this decade 
when their anti-carcinogenic and anti-oxidant effects are unraveled, yet their 
therapeutic potentials have not been fully explored. 
The major aims of this investigation are to examine the effects of baicalein 
and other flavonoids on the proliferation and apoptosis of breast cancer cells. The 
mechanism causing cell death was investigated by using the estrogen-dependent 
MCF-7 and estrogen-independent MDA-MB-231 breast cancer cells. Also, the 
binding affinity for estrogen receptors of these flavonoids was compared. Besides, 
the ERE transactivation activity was investigated. Furthermore, the effects on lipid 
metabolism of baicalein and genistein were compared. From the results, it was found 
that baicalein could be a better natural alternative for the treatment and prevention of 
estrogen-responsive breast cancer. 
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CHAPTER 2 MATERIALS AND METHODS 
2.1 CHEMICALS 
2.1.1 Flavonoids 
All chemicals were purchased from Sigma, USA except as stated otherwise. All 
culture plates and vessels were from CoStar (Cambridge, MA, USA). The flavonoids 
(baicalein, genistein, biochanin A, flavone, quercetin, kaempferol) and 17p-estradiol 
used in this study were purchased from Sigma Chemical Co. (St. Louis, MO, U.S.A.). 
The flavonoids were freshly prepared by dissolving in DMSO while the 
17P-estradiol was dissolved in ethanol and stored at — 20 They were diluted in 
RPMI medium and the final concentration of ethanol and DMSO in the culture 
medium never exceeded 0.1 % (v/v). 
2.1.2 Plasmids 
ERa and P expression plasmid and ERE-luciferase reporter plasmid were gifts 
from Dr. Donald McDonnell, Duke University, NC，U.S.A. Renilla luciferase control 
plasmids were purchased from Promega Corp. 
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2.2 MAMMALIAN CELL CULTURE 
2.2.1 Maintenance of cells 
The hepatocarcinoma cell line HepG2 and the breast cancer cell line 
MDA-MB-231 were obtained from American Type Cell Collection (Rockville, MD， 
U.S.A.), the breast cancer cell line MCF-7 from Dr. V.C. Jordan and MELN cell line 
from Dr. J.C. Nicolas (INSERM, Montpellier, France). The cells were incubated in 
phenol red free RPMI 1640 media with 2 )amol/L L-glutamine (Gibco BRL, 
Rockville, MD, U.S.A.), 100,000 U/L penicillin and 100 g/L streptomycin, and 5% 
fetal bovine serum (FBS) (Gibco BRL, Rockville, MD, U.S.A.). The incubator was 
maintained at 37°C and 5% CO2 air. When cells reached about 80% confluence, the 
culture medium was removed and discarded. The cell layer was rinsed with PBS and 
the cells were trypsinized with 3 ml trypsin-EDTA for 3 minutes. The cell suspension 
was transferred to a 15-ml centrifuge tube containing 7 ml PBS and centrifiiged at 
1,000 rpm at room temperature for 5 minutes. The medium was then removed 
without disrupting the cell pellet. The cells were then resuspensed in appropriate 
fresh growth medium. The cell suspension was added in aliquot into new culture 
vessels. (Sub-cultivation ratio: 1:4 to 1:6) and incubated as described above. 
Four days before the beginning of experiments the cells were switched to the 
same media with 5% charcoal dextran-treated fetal bovine serum (Hyclone, Logan, 
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UT, U.S.A.) instead of FBS. The cells were trypsinized and seeded at a density of 
8,000 cells/ well in 96-well; 10^  cells/ well in 24-well and 5 X 10^ cells/ well in 
6-well Costar culture plates one day before treatment started. 
2.2.2 Preparation of cell stock 
Semi-confluent cells in 75 cm flask were washed with PBS and trypsinized as 
described above. After centrifugation, the cell pellet was suspended in 450 jul of 
RPMI supplemented with 10% v/v FBS and transferred into a 2-ml freezing tube 
containing 500 )al of FBS and 200 jil of DMSO. The tube was put in a isopropanol 
filled freezing pot (Nalgene, USA) and the pot was put into a —80�C freezer so that 
the cell stock was frozen at a constant rate of about r C /min. The frozen vial was 
transferred and stored into liquid nitrogen for permanent storage. 
2.2.3 Cell recovery from liquid nitrogen stock 
The cell stock was taken out from the liquid nitrogen tank and thawed 
immediately in a 37�C water bath. To remove the DMSO, the cell stock was diluted 
into 10 ml of RPMI with 10% v/v FBS. The cell suspension was centrifiiged as 
described above and the supernatant was discarded. The cell pellet was subsequently 
suspended in 10 ml of RPMI with 10% v/v FBS, plated on a 75 cm^ culture flask and 
incubated as above. Medium was changed one day after recovery of the cells. 
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2.3 IDENTIFICATION OF ESTROGENIC ACTIVITY IN 
FLAVONQIDS 
2.3.1 Steady Glo Luciferase Assay 
Procedures and solutions were essentially those provided by the manufacturer 
with slightly modification (Promega). MELN cells were trypsinized and counted. 
The cells were plated into 24 well plate with density 10 .^ After 24 hours, the cells 
were treated with 1 i^l of various concentrations of phytoestrogens. At the end of 
incubation, the growth medium was removed carefully from cells. The cells were 
then rinsed with IX PBS. 100 |LI1 lysis buffer was added to each well. The culture 
vessel was rocked or shaken gently at room temperature for 15 minutes. The lysates 
were transferred into tubes. The cell lysates were centrifoged at 4 10 jil 
supernatant was dispensed into 96 well white plate. 50 jiil of Luciferase Assay 
Reagent was dispensed and luciferase activity was measured. Protein assays were 
performed on each cell lysates according to Bradford ‘s method. 
2.3.2 The BioRad Protein Assay kit (a modified Bradford method) 
The microassay protocol (linear range of 1.2 to 10 jiig/ml) suggested by the 
manufacturer was routinely performed. Protein sample or standard protein was 
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brought to 0.8 ml by dHsO. 0.2 ml of the dye reagent concentrate was added to each 
tube and vortex. The solution was incubated at room temperature for at least 5 
minutes but not more than 1 hour. OD595 was measured. 
Standard curve was obtained by bringing 2, 4, 6，8 and 10 |LI1 of BSA (1 
mg/ml) to 0.8 ml by dHsO and adding the dye reagent concentrate. The O D 5 9 5 
values of the standard proteins were plotted against protein content (2, 4，6, 8 and 
10 |ag) and a linear regression line was obtained. The concentration of sample 
protein was determined by fitting the O D 5 9 5 value to the regression equation. 
2.4 VIABILITY ASSAY 
The viability of cells was assessed using 3-(4，5 dimethylthiazol-2-yl)-2, 
5-diphenyl tetrazolium bromide (MTT) straining. This is a colorimetric assay 
dependent on the cellular reduction of MTT to a blue formazan product by the 
mitochondrial dehydrogenase of viable cells. The intensity of the blue color is a 
measure of cell viability. MCF-7 cells were plated in 96-well plates at 8000 cells per 
well, and 1 |il of various concentrations of phytochemicals were administered for 24 
hours. At the end of incubation, the cells were rinsed with ice-cold PBS. 50 jal (1 
mg/ml) MTT was added into each wells and incubated at 37° C for 3 hours. The 
plate was covered with alumni foil. 100 )al DMSO was added into each well and 
34 
incubated at room temperature for 30 to 40 minutes. The MTT reading was obtained 
by measuring absorbance 540 nm. 
2.5 ERE LUCIFERASE REPORTER GENE ASSAY 
The transfection procedures were performed as previously described (Casanova 
et al. 1999) with slight modification. ER a and p expression and ERE-luciferase 
reporter plasmids were gifts from Dr. Donald McDonnell, Duke University, NC, 
U.S.A. HepG2 cells were cotransfected with three different plasmids, namely, 
ERE-luciferase reporter, ER expression, and Renilla luciferase control plasmids 
(Promega Corp). Lipofectamine (Gibco BRL) was used as the agent of transfection. 
The cells were treated with various concentrations of phytoestrogens with and 
without 17p-estradiol. After 24-hour treatment, the cells were lysed and assayed for 
luciferase activities. A dual-luciferase reporter assay system from Promega Corp 
(Madison, WI, U.S.A.) and a luminometer (Fluostar Galaxy, BMG Labtechnologies 
PTY. Ltd., Australia) were used for this procedure. The reporter firefly luciferase 
activity was measured by adding Luciferase Assay Reagent II from the kit. The 
firefly luciferase was then quenched, followed by the assay of the control Renilla 
luciferase activity. The firefly luciferase activity was a signal representing ER 
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transactivation activity, and the Renilla luciferase reading was employed to 
normalize the transfection efficiency. 
2.5.1 Transient transfection of cell using lipofectamine PLUS reagent 
The day before transfection, the cells were trypsinized and counted. The cells 
were plated into 24-well plate with density 10^  cells/wells. At the time of plating and 
during transfection, avoid antibiotics. 0.4 [ig DNAs were pre-complexed with the 4 
\xl PLUS reagent and diluted into 25 |al medium without serum. It was then incubated 
at room temperature for 15 minutes. 1 jiil of LIPOFECTAMINE Reagent was diluted 
into 25 |al medium without serum in a second tube and mixed. The pre-complexed 
DNAs were combined with the diluted LIPOFECTAMINE Reagent. It was mixed 
I 
and incubated at room temperature for 15 minutes. While complexes were forming, 
I: 
the cells were replaced with 0.2 ml transfection medium. (It was possible to use 
serum in the transfection medium at this step). The DNAs-PLUS-LIOPFECTAMINE 
Reagent complexes were added into each well containing fresh medium on cells. The 
complexes were mixed gentle into the medium. The plate was incubated at 37 °C at 5 
% CO2 for 3 hours. After 3 hours incubation, the volume of medium was increased to 
1 ml with normal growth medium. At the same time, the cells were treated with 1 |LI1 
of various concentrations of phytoestrogens with and without 17P-estradiol. 
36 
2.5.2 Dual Luciferase Assay 
Dual Luciferase assays were preformed according to manufacturer's instruction 
(Promega). 10 )il cell lysates were mixed with 50 |LI1 of reaction buffer supplemented 
with firefly luciferase substrate. The luciferase bioluminescence was measured by 
using a FLUOstar Galaxy plate reader. The ERE transactivation activities represented 
by firefly luciferase light units were then normalized with that of renilla luciferase. 
2 . 6 ER a COMPETITIVE BINDING ASSAY 
An Estrogen-R (a) Competition Screening Kit was obtained from Wako 
Chemicals (Japan) to quantify the competition between estradiol and flavonoids for 
ERa binding. The phytoestrogens were incubated with 10'^  mol/L 
fluorescein-labeled estradiol in a 96-well plate coated with recombinant ERa for 2 h. 
After flushing the wells with wash buffer, the fluorescence was read at excitation 
wavelength 480 nm and emission 530 nm by a Fluorescence plate reader (Fluostar 
Galaxy). 
Six fil of phytoestrogens were mixed with 114 |LI1 of reaction solution. 100 |LI1 
of the prepared mixture was added and incubated with 10"^  mol/L fluorescein-labeled 
estradiol in a 96-well plate coated with recombinant ERa at room temperature for 2 
hours. After flushing the wells with 200 [xl of wash buffer, 100 jal of assay solution 
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was added into each well. The fluorescence was read at excitation wavelength 480 
run and emission 530 nm by a Fluorescence plate reader (Fluostar Galaxy). 
1.1 APOPTOTIC DEATH ASSAY 
A Cell Death Detection Enzyme-Linked Immunosorbent Assay kit (Roche 
Molecular Biochemicals, Mannheim, Germany) was used for this determination. 
Cells with a density of 5 x lOV well were plated in 24-well plates (4 wells/treatment). 
After 48 h of treatment, the cells were washed once with phosphate buffered saline 
(PBS) and lysed with 0.5 ml lysis buffer provided by the kit. DNA fragments were 
then quantified in the cell lysates by ELISA. A similarly treated cell culture plate was 
used for the cell viability determination by 3-(4, 
5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay (Hansen et al., 
1989). The apoptotic index (Al) was then obtained by normalizing the ELISA value 
with the cell viability (MTT absorbance) reading. 
A volume of 100 |il coating solution was pipette into each well of the 
MTP-modules. The MTP-modules was covered tightly with the adhesive cover foil. 
It was incubated at room temperature for 1 hour. The coating solution was removed 
thoroughly by tapping or suction. 200 fil incubation buffer was pipetted into each 
well of MTP-modules. The MTP-modules was covered tightly with the adhesive 
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cover foil and incubated at 15 to 25 °C for 30 minutes. The solutions were removed 
thoroughly by tapping or suction. The wells were rinsed three times with 250 to 300 
|LI1 washing solution per well. The washing solution was removed carefully. 100 jiil of 
sample solution was pipette into each well of the MTP-modules. For the 
determination of the background of the immunoassay, 100 |LI1 of incubation buffer 
was pipette into two wells. The MTP-modules was covered with the adhesive cover 
foil and incubated at 15 to 25 °C for 90 minutes. The solutions were removed 
thoroughly by tapping or suction. The wells were rinsed three times with 250 to 300 
\x\ washing solution per well. The washing solution was removed carefully. 100 of 
conjugate solution was pipette into each well of the MTP-modules, except blank 
position. The MTP-modules was covered tightly with the adhesive cover foil and 
incubated at room temperature for 90 minutes. The solutions were removed 
thoroughly by tapping or suction. The wells were rinsed three times with 250 to 300 
i^l washing solution per well. The washing solution was removed carefully. 100 jiil of 
substrate solution was pipette into each well of the MTP-modules and incubated on a 
plate shaker at 250 rpm until the color development was sufficient for a photometric 
analysis (approximately after 10 to 20 minutes). The content of the wells was 
homogenized by careful tapping at the MTP-modules edges and measured at 405 nm 
against substrate solution as blank. 
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2.8 SEMI-QUANTITATIVE RT-PCR ASSAY 
2.8.1 Isolation of RNA using TRIzol® Reagent (Life Technology, 
USA) 
Total RNA was isolated from cells grown in 6-well Costar plates in triplicates 
by Trizol Reagent as directed by manufacturers (Life Technology, USA). Cells were 
washed with cold PBS twice. 1 ml of TRIzol reagent was added in each well and the 
cells were lysed by passing through a pipette for several times. The homogenous 
samples were incubated at room temperature for 5 min and transferred to a 
microcentrifuge tubes. 0.2 ml of chloroform was added. Then the samples were 
mixed vigorously by shaking for 15 s and were allowed to stand at room temperature 
for 3 min. The samples were then subjected to centrifugation at 12 ,000 g for 15 min 
at 4°C. Afterward, the upper aqueous layer was transferred to another 
microcentrifuge tube containing 0.5 ml isopropanol. The samples were incubated at 
room temperature for another 10 min and centrifuged at 12 ,000 g for 10 min at 4°C. 
The supernatant was removed and the RNA pellet was washed with 1 ml of 75 % 
ethanol by vortexing. Then the RNA was collected as repellets and air dried. 30 ]il of 
DEPC water was added to redissolve the RNA which was then stored at -80°C. 
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2.8.2 Quantitation of RNA 
The FLUOstar Galaxy was used for quantitation of nucleic acid. An 1 OD unit 
at 260 nm corresponds to 50 jiig/ml double-stranded DNA, 40 jiig/ml single stranded 
DNA and RNA, 20 fxg/ml single -stranded oligonucleatide. The amount and purity 
of RNA were determined by measuring its absorbance at 260nm and 280nm. OD260 * 
40 mg ml-i = Amount of RNA (mg ml"^). RNA isolated by this method exhibited a 
260/280 ratio o f �1 . 6 . 
2.8.3 First strand cDNA synthesis 
A reverse transcription-polymerase chain reaction (RT-PCR) assay was used to 
quantitate Bcl-2, Bax and PS2 mRNA level. Primers of Bcl-2, Bax, PS2 and p-actin, 
sequences as published formerly (Wang et al. 1995; Wang et al. 1996) were utilized 
to amplify the target cDNAs separately after the first strand reaction. 
A 20 |Lil reaction volume was used for 1 ng - 5 jig of total RNA. The following 
components were added to a nuclease-free microcentrifuge tube: 
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Sterile ciH20 10-X i^l 
Oligo (dT)i2-i8(500 |ag/ml) 1 
DNTP (10 mM, 2.5 mM each of 1 
dATP, dCTP, dGTP and dTTP) 
RNA X^il 
Total 12 
The mixture was heated to 65 for 5 minutes and chilled on ice quickly. The 
contents of the tube were collected by brief centrifUgation. The following 
components were added: 
5X First-Strand Buffer 4 jul 
0.1 MDTT  
Total 18 
The contents was mixed gently and incubated at 42 for 2 min. 1 |LI1 (200 units) 
of SUPERSCRIPT II was added and mixed by pipetting gently up and down. The 
mixture was incubated at 42 for 50 min. The reaction was inactivated by heating 
at 70 for 15 min. The cDNA was used as a template for amplification in PGR. 
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2.8.4 PCR reactions 
The reaction mix was prepared in the sequence depicted as follows unless 
Sterile dH20 (41-X) 
1 OX PCR reaction buffer with 50 mM MgC12 5 
dNTP (10 mM, 2.5 mM each of 1 |Ltl 
dATP, dCTP, dGTP and dTTP) 
Forward Primer (10 jiM) 1 jul 
Reverse Primer (10 ^M) 1 jiil 
Template cDNA X |LI1 
Tag DNA polymerase (5U/|LI1) 0.4 [ul  
Total 50 III 
20 cycles for Actin and 30-35 cycles for Bcl2 and Bax of amplification were 
performed with a denaturation temperature 94 for 45 s, an annealing temperature 
65 for 45s and extension temperature of 72 for 2 min. After reaction, the 
mixture was analyzed by 1.8 % agarose gel electrophoresis or stored at 4 for short 
period of time or -20 for long-time storage. 
2.9 FLOW CYTOMETRY ANALYSIS 
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MCF-7 cells were trypsinized and counted. The cells were placed into 6-well 
plate with density 5X105. After 24 hours, the cells were treated with 1 jil of various 
concentrations of phytoestrogens. At the end of incubation, the growth medium was 
removed carefully from cells. The cells were then rinsed with IX PBS. Cells were 
trypsinized, washed with PBS twice, and fixed in 1 ml ice-cold 70% ethanol. The 
suspension was kept at 4 °C overnight. The cells were centrifuged and washed with 
PBS. The cells were stained with a 1 ml solution containing 40 jtig/jil of propidium 
iodide and 8 |ig/|il of RNaseA at 37 C for 30 minutes. Cell cycle distribution was 
analyzed with a FACSort machine (Becton Dickinson, USA). 
2.10 T O T A L T R I G L Y C E R I D E A N D C H O L E S T E R O L 
M E A S U R M E N T S 
HepG2 cells were preincubated overnight in serum free medium supplemented 
with 1 % BSA. The following day, after moving the media, the cells were incubated 
for additional 24 hours in 1 ml media containing appropriate compounds 
(17P-estradiol，baicalein and genistein) with or without free fatty acid. Another 
experiment with or without VLDL (50 |Lig/ml) was carried out. At the end of the 
incubation period, the cells were washed 3 times with 1 ml ice-cold PBS, and the 
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soluble cell protein was dissolved in 1 ml 0.1 mol/1 NaOH and measured using the 
method of Bradford with BSA as the standard. 
To determine the intracellular triglyceride and total cholesterol, after washing 3 
times with ice-cold PBS, the cells were treated with 1 ml hexane-isopropanol (2:1) at 
room temperature for 30 minutes. These samples were transferred to test tubes. The 
wells were washed with 1 ml hexane-isopropanol, and the washing solutions were 
also transferred to the corresponding teat tubes. The organic solvent was removed 
under nitrogen. The lipids were resuspended in DMSO. 
2.10.1 Determination of the total cholesterol 
Procedures and solutions were essentially those provided by the manufacturer. 
The spectrophotometer wavelength was set at 500 nm for the absorbance 
measurement. Water was used as the reference. The Cholesterol Reagent was 
wanned to assay temperature. An aliquot of 1 ml of reagent was pipetted into tubes. 
Deionized water (10 )al), Calibrator, Control and samples were added to 
appropriately labeled cuvets. The cuvets were incubated at 37 °C for 30 minutes. The 
absorbances of all tubes at 500 nm were read and recorded. 
Calculations: 
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Cholesterol (mg/dL) = Atest-Ablank X Calibrator (mg/dL) 
Acalibator-Ablank 
2.10.2 Determination of the total triglyceride 
Procedures and solutions were essentially those provided by the manufacturer. 
The spectrophotometer wavelength was set at 540, and the absorbance reading to 
zero with water as reference. The Triglyceride Working Reagent was warmed to 
assay temperature. An aliquot of 1 ml of reagent was pipetted into tubes. Deionized 
water (10 |al), Calibrator, Control and samples were added to appropriately labeled 
cuvets. The cuvets were incubated at 37 ° C for 5 minutes. The absorbances of all 
tubes at 540 nm were read ad recorded. 
Calculations: 
Cholesterol (mg/dL) = Atest-Ablank X Calibrator (mg/dL) 
Acalibator-Ablank 
2.11 MANIPULATION OF DNA AND R N A 
2.11.1 Transformation of DH5a 
An amount of 1 |Lig of plasmid DNA was transferred into a 1.5-ml microfuge 
tube containing 200 |LI1 of competent DH5a or BL21(DE3) cells and left on ice for 30 
min. The cells were placed into 42 water bath for 1.5 min for heat shock and 
chilled on ice for 3 min for cold shock. The transformation mix was mixed with 1 ml 
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of LB medium and incubated at 37 °C in a shaker for 30 min. The mixture was then 
centrifUged at 1,000 rpm in a desktop centrifuge for 5 s，and 900 of the 
supernatant was discarded. The pellet was resuspended in the residual medium and 
plated on LB^P plate and incubated at 37 °C overnight. Transformants that grew on 
plate as single colonies were transferred into 2 ml of LB^P medium with toothpicks 
and incubated at 37 °C with shaking overnight. The cultures were screened by PGR 
with appropriate primers and analyzed with agarose gel electrophoresis. 
Transformants that scored positive with the PCR screening were further analyzed by 
restriction digest after mini-prep. One of the transformants was then inoculated into 
200 or 500 ml of LB^ ^^ P medium and grew with shaking at 37 °C overnight. 
Large-scale plasmid isolation (maxi- or giga-prep) was then performed. 
2.11.2 Minipreparation of plasmid DNA 
Procedures and solutions were essentially those provided by the manufacturer. 
A single bacterial colony on LB plate with appropriate antibiotic was inoculated into 
3 to 5 ml of LB medium containing appropriate antibiotic in a 14 ml polypropylene 
round-bottom tube. The culture was incubated at 37 °C at 250 rpm for 14 to 16 hours. 
Bacterial pellet was collected by centrifugation at 12,000 g for 2 minutes in a 
microfUge. The pellet was resuspended in 300 PI containing 100 jiig/ml RNase A 
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in a 1.5 ml microfiige tube. After 300 \i\ of P2 was added, the bacterial lysate was 
mixed by inversion for 3 to 5 times and allowed to stand on ice for 5 minutes. Then 
300 |il of P3 was added, mixed by inversion and the tube was allowed to stand on ice 
( 
for 15 minutes. Cell debris and chromosomal DNA were removed by centrifugation 
at 12,000 g for 15 minutes at 4 °C. The supernatant containing plasmid DNA was 
transferred to a fresh microfuge tube and re-centrifiige of white precipitate was 
present. The plasmid DNA was recovered by ethanol precipitation and was dissolved 
in 15 )Lil of sterile water and stored at -20 °C. 
2.11.3 Preparation of plasmid DNA using QIAGEN-tip 100 
midi-prep kit 
Procedures and solutions were essentially those provided by the manufacturer. 
A single colony colony of bacterial on an LB agar plate with antibiotic was 
inoculated to 100 ml of LB medium containing appropriate antibiotic and incubated 
for 14 to 16 hours at 37 °C at 250 rpm. Bacterial pellet was collected by 
centrifugation at 6，000g for 10 minutes at 4 °C. The pellet was resuspended in 4 ml 
PI containing 100 pg/ml RNase A. Then 4 ml of P2 was added to the suspension 
which was allowed to stand on ice for 5 minutes. 4 ml of P3 was then added to the 
mixture which was incubated on ice for 15 minutes. Cell debris and chromosomal 
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DNA were removed by centrifugation at 20,000g for 30 minutes at 4 °C. The 
supernatant was then transferred to a fresh centrifuge tube and re-centrifuged to 
obtain a clear lysate. A QIAGEN-tip 100 was equilibrated with 4 ml of QBT with 
flow maintained by gravity. The clear lysate was then applied to then column. After 
all the lysate had passed through the column, the column was washed with 2X 10 ml 
of QC. The adsorbed plasmid DNA was then eluted with 5 ml of QF. The eluted 
plasmid of DNA was then precipitated with 3.5 ml (0.7 volume) of room temperature 
isopropanol and centrifuged immediately at 15,000g at 4 °C for 30 minutes. The 
supernatant was removed carefully not to disrupt the chalky white DNA pellet which 
was then washed with 70 % ethanol and re-centrifuged. The washed plasmid DNA 
was the dried by air for 5-10 minutes and dissolved in 100 fil of sterile water and 
stored a t - 2 0 
2.11.4 Preparetion of plasmid DNA using QIAGEN-tip 10000 
Giga-prep kit 
Procedures and solutions were essentially those provided by the manufacturer. 
A two-liter of bacterial culture was harvested by centrifugation at 6,000 rpm at 4 � C 
for 10 minutes. The bacterial pellet was resuspended in 125 ml of buffer PI 
thoroughly. A volume of 125 ml of buffer P2 was added and mixed by inverting 4 to 
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6 times ad the suspension was incubated at room temperature for 5 minutes. A 
volume of 125 ml of buffer P3 was added and mixed immediately by inverting 4 to 6 
times, not included on ice as recommended by manufacturer. Cell debris and 
chromosomal DNA were removed by centrifugation at 20,000 g for 30 minutes at 4 
°C. The supernatant containing plasmid DNA was transferred to a fresh centrifuge 
tube and centrifuged at 20,000 g for 15 minutes. A QIAGEN-tip 1000 was 
equilibrated by applying 75 ml buffer QBT, and the column was allowed to empty by 
gravity flow. The supernatant was then applied to the QIAGEN-tip and entered the 
resin by gravity flow. The column was washed by 2X 300 ml buffer QC and then 
eluted by 75 ml QF. The eluted DNA was precipitated by 52.5 ml (-0.7 volume) of 
room temperature isopropanol and centrifuged immediately at 15,000 g for 30 
minutes at 4 °C. the supernatant was decanted carefully and the DNA pellet was 
washed with 10 ml room temperature 70 % ethanol and centrifuged at 15,000 g for 
30 minutes at 4 °C. The supernatant was decanted carefully and the pellet was dried 
by air for 10- 20 minutes. The DNA was redissolved in suitable volume of sterile 
water. The yield of plasmid preparation was determined by FLUOstar Galaxy at 260 
and 280 nm. 
2.11.5 Ethanol preparation of DNA and RNA 
One-tenth volume of 3.0 M sodium acetate (pH 5.2) and 2 volumes (for DNA) 
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or 2.5 volumes (for RNA) of cold 100 % ethanol were added to a DNA or RNA 
solution. The nucleic acid was precipitated at -70 °C for 30 minutes. The precipitate 
was centrifuged at 12,000 g for 10 minutes at 4 � C ad then dried in SpeedVac (Savant 
Instruments Inc.) for DNA or dried by standing on bench for 5 minutes for RNA. The 
nucleic acid was then dissolved in sterile water for DNA or DEPC- treated water in 
an appropriate volume. 
2.11.6 Agarose gel electrophoresis of DNA 
The agarose gels were prepared with 1.8 % (w/ v) agarose dissloved in IX TAB 
buffer containing 0.5 jiig/ml ethidium bromide. The volumes of DNA samples were 
adjusted to 10, 20 or 50 |il with water or the running buffer with addition of 6X 
loading buffer (section) to a final concentration of IX. After loading the samples into 
the wells of the gel, electrophoresis was performed at constant voltage of 90 to 125 V 
(10 to 14 V/ cm) in a gel tank containing appropriate IX TAB buffer. When 
electrophoresis was finished, DNA was visualized on a Spectroline model TC-302 
transilluminator (302 nm) and, if necessary, photographed with a Polariod MP-4 
instant camera. 
51 
2.12 STATISTICAL METHODS 
A Prism 3.0 software package (GraphPad Software, Inc., CA，U.S.A) was 
utilized for statistical analysis. The results, whenever applicable, were analyzed by 
One-way ANOVA followed by Dunnett's Multiple Comparison Test if significant 
(户<0.05) differences observed. The ER transactivation luciferase activities and the 
ER competitive fluorescence readings were curved-fitted by sigmoidal dose-response 
built-in equations, which automatically calculated the EC50 or IC50 values. 
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CHAPTER 3 ESTROGENIC AND ANTIPROLIFERATIVE 
ACTIVITIES ON MCF-7 BREAST CANCER CELLS BY 
FLAVONOIDS 
3.1 INTRODUCTION 
Baicalein is a flavone isolated from the plant Scutellariae radix, which is 
commonly used for herbal medicine or tonic in Asian countries. The flavonoid has 
modulating effects on drug metabolizing enzymes (Ueng et al. 2000), and 
anti-proliferative effects on prostate cancer cells (Chan et al. 2000), hepatoma cells 
(Motoo et al. 1994), vascular smooth muscle cells (Huang et al. 1994). Baicalein has 
also been described as an antioxidant (Chen et al. 2000)，anti-inflammatory agent 
(Lin et al. 1996), and an inhibitor to prostaglandin E2 (Nakahata et al. 1998). 
Many studies have illustrated that genistein can modulate the activity of 
estrogen by way of receptor binding. Because of the structural similarity to genistein, 
other flavonoids were explored for their SERM application. In this study a group of 
dietary flavonoids were screened for their antiestrogenic property and their ability to 
induce cell death in breast cancer cells were compared. Their chemical structures are 

















HO y ^ 




^ ^ 严 H 3 







Figure 3.1 Chemical structures of phytoestrogens. A: Baicalein; B: Flavone; C: 
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Kaempferol; D: Quercetin; E: Biochanin A and F: Genistein. 
3.2 RESULTS 
Screening of phytoestrogens for estrogenic activities on MELN cells 
The interaction between the estrogen receptor and a variety of flavonoids was 
studied using stably transfected human breast cancer cell line (MELN). All 
phytoestrogens induced luciferase transcription at all concentration tested shown in 
Figure 3.2. Genistein initiated near 9 times while baicalein initiated near 2 times the 
control luciferase activity at 1 |Limol/L concentration tested. At 50jLimol/L 
concentration tested, genistein induced near 14 times the control activity but it is 
only 4 times the control activity for baicalein. A dose-response relationship was 
demonstrated even though it was not linear. 丨 
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Figure 3.2 Luciferase induction by phytoestrogens in MELN cells. MELN cells 
were seeded in 24-well culture plates. Phytoestrogens at 0, 1, 10 and 50 jumol/L were 
administered. After 24 h of treatment, cells were lysed and assayed for luciferase 
activities. Values are means 士SEM，n=3. Means marked (*) significantly (尸<0.05) 
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Cell proliferative activity of phytoestrogens on MCF-7 and MDA-MA231 cells 
Flavonoids were evaluated for their effects on proliferation in 
estrogen-dependent (MCF-7) and independent (MDA-MB31) human breast cancer 
cells. At low concentration, these phytoestrogens enhanced proliferation of MCF-7 
cells. The response was dose-dependent as shown in Figure 3.3. Baicalein induced 
the most estrogenic responsive MCF-7 cell death while genistein induced the least 
estrogenic responsive MCF-7 cell death started from 10 |Limol/L. All phytoestrogens 
had significant cell death effect on MCF-7 cells line at 50 jimol/L. On the contrary, 
these phytoestrogens inhibited the proliferation of MDA-MB231 cells started from 1 
|amol/L as shown in Figure 3.4. And, there was no differential effect of cell death 
among the flavonoids tested on MDA-MB231 cells The difference in the ability for 
causing cell death of these phytoestrogens between the two cell lines was related to 
the existence of estrogen receptors. 
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Figure 3.3 Effects of phytoestrogens on the proliferation of MCF-7 cells. MCF-7 
cells were seeded in 96-well culture plates. Phytoestrogens at 0, 0.1，1, 10 and 50 
|amol/L were administered. After 48 h of treatment, MTT assay was performed. 
Values are means 士SEM，n=8. Means marked (*) significantly (P<0.05) differ from 




































































































Figure 3.4 The effect of phytoestrogens on the proliferation of MDA-MB231 
cells. MDA-MB231 cells were seeded in 96-well culture plates. Phytoestrogens at 0， 
0.1，1，10 and 50 jimol/L were administered. After 48 h of treatment, MTT assay was 
performed. Values are means 士SEM, n=8. Means marked (*) significantly (户<0.05) 
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Estrogenic and antiestrogenic activity of phytoestrogens on ERa or ERp 
transfected HepG2 cells 
All phytoestrogens exhibited a significant degree of estrogenic activity in both 
ERa and ERp transfected HepG2 cells. Among these compounds, the most active 
flavonoids at 10 and 25 |xM was genistein while baicalein was the most potent 
antiestrogen and the weakest estrogen among all the tested phytochemicals as shown 
in Figure 3.5 and 3.6 showed that baicalein was the weakest estrogenic compound 
for both estrogen receptor a and p. 
The estrogenic activities of these flavonoids were studied in the presence of 
10-9 M 17p-estradiol to evaluate the antiestrogenic activity of the flavonoids. Figure 
3.7 and 3.8 demonstrated that baicalein suppressed ER a and P mediated 
transactivation while the other phytoestrogens showed little or no suppression on ER 
a and p mediated transactivation. 
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Figure 3.5 Effects of phytoestrogens on ERa transactivation activities. HepG2 
cells were seeded in 24-well culture plates and transient transfected with ERa 
expression, control and ERE-luciferase reporter plasmids for 6 h. Phytoestrogens at 
0，10 and 25 |Limol/L were administered. After 24 h of treatment, cells were lysed 
and assayed for dual luciferase activities. Values are means 士SEM, n=3. Means 
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Figure 3.6 Effects of phytoestrogens on ERp transactivation activities. HepG2 
cells were seeded in 24-well culture plates and transient transfected with ERp 
expression, control and ERE-luciferase reporter plasmids for 6 h. Phytoestrogens at 
0, 10 and 25 |amol/L were administered. After 24 h of treatment, cells were lysed 
and assayed for dual luciferase activities. Values are means 士SEM，n=3. Means 






































































































Figure 3.7 The antagonistic effects of phytoestrogens on ERa . Cells were treated 
exactly the same as Figure 3.5 except 10'^  M 17P-estradiol was co-administered 
with the phytoestrogen. Treatment (*) is significantly higher than the control (0 
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Figure 3.8 The antagonistic effects of phytoestrogens on ERp. Cells were treated 
exactly the same as Figure 3.6 except 10'^  M 17p-estradiol was co-administered 
with the phytoestrogen. Treatment (*) is significantly higher than the control (0 
lamol/L) (P<0.05, ANOVA; Values are means 士SE，n=3). Values are means 士SEM， 























































































In this study, these six flavonoids were firstly screened for their estrogenic 
activities in MELN cells that were stably transfected with luciferase reporter gene. 
All flavonoids showed estrogenic response but with different estrogenicity. The order 
of estrogenicity is genistein�biochanin A> flavone�kaempferol�quercetin� 
baicalein, as shown in Figure 3.2. The six flavonoids were proved for their ability to 
produce estrogenic response in breast cancer cells. 
Also, the flavonoids were evaluated for their effects on proliferation in 
estrogen-dependent (MCF-7) and independent (MDA-MB231) human breast cancer 
1 
cells. Baicalein could cause a greater amount of cell death in an ER-positive breast ‘ 
li 
cancer line MCF-7 than the other flavonoids, but the differential effect was not seen in 
the ER-negative MDA-MB231 breast cancer cells. Exposure to estrogen has been 
considered a risk factor of breast cancer because of its ability of causing cell 
proliferation (Nenci et al. 1998). Many studies have been shown that gensitein and 
other phytoestrogens display biphasic effect on the proliferation (Le Bail et al. 1998) 
and death (So et al. 1997) of MCF-7 cells. In these studies the proliferating phase is 
believed to be under the influence of estrogen-like activity of the phytoestrogens, 
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while the antiestrogenic property exerts its effect on the cytotoxic phase. From the 
result of Figure 3.3, all flavonoids except baicalein induced cell growth from 
concentration 0 to 1 i^ imol/L and caused cell death at concentration higher than 1 
fimol/L. They displayed biphasic effects on proliferation and death of MCF-7 cells. By 
contrast recent advancement has suggested that the ER-dependent pathway is only 
responsible for the proliferative phase (Maggiolini et al. 2001), and the ER agonistic 
nature of genistein and other flavonoids encouraged cell growth at low concentrations. 
In this study baicalein did not show a biphasic effect in MTT assay in MCF-7 cells 
shown in Figure 3.3, and its ER antagonistic property could contribute to the lack of 
growth stimulus at low concentrations. In turn, the lack of proliferating phase might 
j 
account for the potent cell death inducing action on MCF-7 cells. Moreover, it seems 
- 1 
that flavonoids at high concentrations or in estrogen-independent (MDA-MB231) 
I, 
I: 
human breast cancer cells exert their antiproliferative activity through other estrogen 
receptor-independent mechanisms. 
On the other hand, the interaction between the estrogen receptor and a variety of 
flavonoids was studied in the presence or absence of estradiol using a transient 
transfected hepatoma cells (HepG2). Baicalein was the most potent antiestrogenic 
and genistein was the most potent estrogenic compound among the tested flavonoids 
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in the presence or absence of estradiol on both estrogen receptor (ER) alpha and beta. 
Baicalein at a considerably low dose (10 |amol/L) could suppress estradiol-induced 
transactivation in both estrogen receptor (ER) alpha and beta. The antiestrogenic 
effect could be explained by the fact that baicalein was a relative strong competitor to 
estradiol for receptor binding. 
A structure-activity relationship was established and the regions and/or 
substituents essential for estrogenic and proliferative activities were determined. 
Among all flavonoids used, only baicalein at high concentrations (10 jimol/L) 
possess both antiestrogenic and antiproliferative activities. These results suggest that 
i 
the hydroxyl group at Re is essential to enchance the antiestrogenic and 
！ 
antiproliferative activities of baicalein. 
if' 
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CHAPTER 4 INTERACTION OF BAICALEIN WITH 
ESTROGEN RECEPTORS 
4.1 INTRODUCTION 
Estrogen receptor (ER) is an intranuclear binding protein, which has a DNA 
binding domain (DBD) and a ligand binding domain (LBD) (Pike et al. 2000). When 
the LBD is bound to a ligand, the ER protein will experience a conformational 
change and initiate transcriptional by attaching to an estrogen response elements 
(ERE) in gene-specific promoter region. Recently two subtypes of ERs known as 
I 
, i 
alpha and beta have identified, and their differences in tissue distribution and ligand 
• I 
I 
affinity have been explored in the treatment of estrogen-related diseases (Dechering 
I. 
et al. 2000). 
The flavonoids are competitor to estrogen for ER binding in a radiolabeled ER 
competition assay system (Kuiper et al. 1997). Because LBD and DBD are in 
separate domains, the antiestrogenic effects of the flavonoids were investigated by 
using a transient transfection cell culture model. This system included a sequential 
events that occurred after activation of ER. 
To determine the affinity of the flavonoids for ERa and ERp, the in vitro 
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cell-free system competition assay and the in vivo ERE-luciferase reporter assay 
were performed and compared. The binding affinities IC50 and EC50 of the flavonoids 
were determined from the competition curves. 
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4.2 RESULTS 
Estrogen receptor competition assay 
From the result of Chapter 3，the transient transfection screening suggested 
baicalein was the strongest antiestrogen among the most common flavonoids. This 
cell-free system competition assay was performed to evaluate the phytoestrogens 
affinity for estrogen receptor. Not surprisingly, baicalein was the strongest among the 
tested as shown in Figure 4.1. The estimated affinity was estimated 1,000-fold 
weaker than 17P-estradiol, while genistein was about half of the strength of baicalein 
in ER affinity. The IC 50 of these flavonoids were determined by using nonlinear 
regression of prism program in this result shown in Table 4.1. 
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Figure 4.1 The competition between phytoestrogens and 17 p-estradiol for 
binding to ERa. Various concentrations of phytoestrogens were mixed with 10"^  
mol/L flurescein-labeled 17p-estradiol, and the mixture was then added to a plate 
coated with recombinated human ERa. The IC 50 of these phytoestrogens were 
estimated. Values are means 士SEM, n=3. Means marked (*) significantly (P<0.05) 
differ from control (0 jumol/L) for estradiol while means marked (**) significantly 



















































































Table 4.1 I C 5 0 values for estradiol, quercetin, kaempferol, baicalein, genistein, 
flavone and biochanin A. 
IC 50 
Estradiol 24 nmol/L 
Quercetin 32 |xmol/L 
Kaempferol 30 |amol/L 
Baicalein 16 |imol/L 
Genistein 34 |imol/L 
Flavone 21 |amol/L 
Biochanin A 31 |imol/L 
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ERE-Luciferase gene reporter assay 
Both genistein and baicalein were agonists at both ERa and ERp (Figure 
4.2 and 4.3). Estradiol was about 1,000-fold more potent than genistein and baicalein 
at both ERa and ERp. Genistein was about 7-fold potent than that of baicalein at both 
ERa and ERp. (Table 4.2) There was no significant difference in potency of estradiol, 
genistein and baicalein to ERa and ERp. The EC 50 of these flavonoids were 
determined by using nonlinear regression of prism program. 
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Figure 4.2 Activity of estradiol, genistein and baicalein at human ER a. HepG2 
cells were transfected with ERa expression, control and ERE-Luc plasmids. Cells 
were treated with increasing concentrations of estradiol, genistein and baicalein. 
Following 24-h incubation, cultures were assayed for dual luciferase assay. Values 





































































Figure 4.3 Activity of estradiol, genistein and baicalein at human ER p. HepG2 
cells were transfected with ERp expression, control and ERE-Luc plasmids. Cells 
were treated with increasing concentrations of estradiol, genistein and baicalein. 
Following 24-h incubation, cultures were assayed for dual luciferase assay. Values 


































































































































Table 4.2 E C 5 0 values for transactivation for human ER a and ER p by estradiol, 
genistein and baicalein. 
Receptor Estradiol Genistien Baicalein 
ERa 0.23 nM 2.5|iM 17|aM 
ERp 0.25nM 2 _ 
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4.3 DISCUSSION 
Estrogenic responses are mediated through two separate estrogen receptors, 
ERa and ERp. These two receptors have homologous DNA and ligand binding 
regions (Kuiper and Gustafsson 1997)，and most compounds have similar binding 
affinities and transcriptional activities with ERa and ERp. By observing the IC50 and 
EC50 values of these flavonoids from the ER competitive fluorescence readings and 
ER transactivation luciferase activities, the relative receptor binding affinities can be 
compared. 
The flavonoids bound to the LBD in the in vitro cell-free system competition 
assay, estradiol was about 1,000-fold more potent than all flavonoids tested at both 
ERa and ERp. Baicalein was found to be the strongest antiestrogen with IC50 16 \iM 
while IC50 of flavone< kaempferoK biochanin A< quercetin< genistein. However, 
ligand binding affinities for the ER does not predict the biochemical or physiology 
effects of a compound and this is related to multiple factors required for ER action 
(Yoon et al. 2000). 
Recent studies using synthetic peptides targeted to the surface of the 
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ligand-bound ER show that various ER ligands known to produce distinct biological 
effects also induce distinct conformational changes in the ER. Thus, these studies 
correlate conformational change of the ligand-bound ER with biological activity. 
Conformational changes induced by various ER ligands most likely alter the 
interactions of the ER with nuclear factors and transcriptional machinery (Yoon at al. 
2000). 
At the same time, the flavonoids bound to DBD in vivo ERE-luciferase reporter 
assay was performed. Undoubtedly, estradiol effectively triggers both ERa and 
ERp -mediated transcriptional activation pathway (An at el. 2001). In this study, 
genistein was about 7-fold potent than that of baicalein at both ERa and ERp. 
Genistein was more effective reagent for ERE transactivation activity than that of 
baicalein in both ER isoforms. Therefore, baicalein was the most potent antiestrogen 
among flavonoids tested and produced weaker ERE transactivation compared to 
genistein at both ER alpha and beta. 
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CHAPTER 5 BAICALEIN AND GENISTEIN DISPLAY 
DIFFERENTIAL ACTIONS ON ER TRANSACTIVATION 
5.1 INTRODCUTION 
Many studies have shown that genistein is an agonist of ER, either in an animal 
model (Makela et al. 1995) or in cell culture models (Miodini et al. 1999; Fioravanti 
et al. 1998; Wang et al. 1996). Others claimed that genistein is an antagonist of ER. 
Kuiper et al. (1997) have expressed rat ERa and ERp and found that genistein 
competes with 17(3- estradiol for the ligand binding domain of ERa and p. These 
results and the present study suggested that the receptor binding replacement of 
estrogen by genistein could not stop the initiation of ERE transactivating events. 
I 
ERa plays a crucial role in growth and differential of mammary gland, but its role in 
carcinogenesis had not been desirable. By constract, the role of ERp in breast cancer 
has been defined. Premalignant breast tissue expresses more ERa than normal breast 
tissue (Allred et al. 2000). The ERs gene, however, is most lost in more advanced 
type of breast tumor (Sheng et al. 1996). 
The estradiol and ER interaction can be multifaceted. There are at least four 
known estradiol-initiated signaling pathways as reviewed (Hall et al. 2001). Two of 
90 
them require the presence of ERE, and others are ERE-independent. AP-1 (Paech et 
al. 1997)，Sp-1 (Batistuzzo de Medeiros et al. 1997), raloxifen response element 
(Yang et al. 1996), and genes containing the antioxidant response element (Montano 
et al. 1997) are all responsive to estrogen administration. In this study the classical 
ERE dependent pathways was examined, genistein was not an effective antagonist to 
estradiol. However, the possibility for genistein antagonizied the ERE-independent 
signaling pathways could not been ruled out. It had been demonstrated that genistein 
may selectively generate an activation function-2 surface of ERp that recruits 
coregulators for the repression and activation of transcription (An et al. 2001) 
Considering the influences on the promoters, it is still possible that genistein can be a 
pro- or antiestrogen modulating transcription processes other than that dictated by 
ERE or ERa. 
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5,2 RESULTS 
Estrogenic and antiestrogenic activities of genistein and baicalein on ER 
transactivation 
Transient transfection assays revealed that baicalein antagonized the 
estradiol-induced ER transactivation in a dose dependent manner as shown in Figure 
5.1 and 5.2. Gensitein, however, showed a biphasic effect on the estradiol-induced 
transactivation as shown in Figure 5.3 and 5.4. At 10 |amol/L genistein 
synergistically increased the estradiol-induced ERE response, whereas the ERE 
response was suppressed at high concentrations. Figure 5.5 and 5.6 was a tamoxifen 
control demonstrating that the transfection system was valid. 
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Figure 5.1 Dose-response antiestrogenic effect of baicalein on ERa. HepG2 cells 
were transfected with ERa expression, control and ERE-Luc plasmids and titrated 
the ERa transactivation response of baicalein on various concentrations of 17P-
estradiol. Each of four baicalein concentrations (0, 10, 50, 100 )imol/L) was tested on 
the antagonistic effect of estradiol ranged from to 10'^  mol/L. Values are means 


































































































































































Figure 5.2 Dose-response antiestrogenic effect of baicalein on ERp. HepG2 cells 
were transfected with ERp expression, control and ERE-Luc plasmids and titrated 
the ERp transactivation response of baicalein on various concentrations of 17p-
estradiol. Each of four baicalein concentrations (0，1, 10, 50 |imol/L) was tested on 
the antagonistic effect of estradiol ranged from lO'" to 10"^  mol/L. Values are means 
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Figure 5.3 Dose-response antiestrogenic effect of genistein on ERa. HepG2 cells 
were transfected with ERa expression, control and ERE-Luc plasmids and titrated 
the ERa transactivation response of genistein on various concentrations of 17p-
estradiol. Each of four baicalein concentrations (0，10, 100 jimol/L) was tested on the 
antagonistic effect of estradiol ranged from to 10'^  mol/L. Values are means 



























































































































Figure 5.4 Dose-response antiestrogenic effect of genistein on ERp. HepG2 cells 
were transfected with ERp expression, control and ERE-Luc plasmids and titrated 
the ERp transactivation response of baicalein on various concentrations of 17P-
estradiol. Each of four genistein concentrations (0, 10, 100 |imol/L) was tested on the 
antagonistic effect of estradiol ranged from 10' to 10' mol/L. Values are means 















































































Figure 5.5 Dose-response antiestrogenic effect of tamoxifen on ERa. The 
response of tamoxifen on estradiol was used as a positive control. Values are means 
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Figure 5.6 Dose-response antiestrogenic effect of tamoxifen on ERp. The 
response of tamoxifen on estradiol was used as a positive control. Values are means 
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5 3 DISCUSSION 
As the screening test indicated baicalein could be a potent antiestrogenic 
phytochemical, the dose-respond suppression of ERE transactivation for both ER a 
and p were estimated subsequently. Figures 5.5 and 5.6 showed the suppression 
results represented by the classic antiestrogen tamoxifen on ER a and |3. Figure 5.1 
and 5.2 denoted baicalein，s suppressions on the two ER isoforms respectively. 
Tamoxifen was a stronger antiestrogen than baicalein. Moreover, tamoxifen appeared 
to be preferably antagonizing ER a, whereas baicalein was antagonistic to both 
isoforms. 
Estrogen has long been considered a promoter of breast cancer for its cell 
proliferative effect. Genistein displayed a biphasic effect on the proliferation and 
death of MCF-7 cells as discussed in Chapter 3. It is believed that the estrogenic and 
antiestrogenic properties of the phytoestrogens control the phases of proliferation and 
cytotoxicity, respectively. Genistein showed an additive effect on estradiol-induced 
ER a transactivation at the tested concentrations. This illustrated that genistein could 
not counteract the ERE binding activity and the estrogen-responsive gene 
transcriptions initiated by estradiol. The replacement of genistein for estradiol still 
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activated ERE transactivation, and the genistein-ER interaction activates the 
tanscriptional complex. Similar activities have been detected (Kuiper at el. 1997). At 
10 jamol/L genistein synergistically increased the estradiol-induced ERE response, 
whereas the ERE response was suppressed at high concentrations. However, both 
baicalein and tamoxifen suppressed the estradiol-induced ERE response at any 
concentrations tested. 
Tamoxifen has been used as an adjuvant therapy for breast cancer patients. Its 
side effect has limited its application as a chemoprevention agent prescribed to those 
at high risk of breast cancer. The antiestrogenic strength of baicalein as shown in this 
study could serve this preventive purpose. Baicalein is a natural compound, and 
people in some parts of China are using the herbs from which baicalein is extracted 
as a health drink ingredient. No cases of toxicity have been reported thus far. 
Nevertheless the efficacy and side effects of the herbal chemicals must been 
addressed. 
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CHAPTER 6 APOPOTOTIC EFFECTS OF BAICALEIN ON 
MCF-7 AND MDA-MB-231 CELL LINES 
6.1 INTRODUCTION 
Apoptosis is a process that controls the growth and development of organisms. 
Perturbation of this process is considered a crucial part of cancer prevention and 
therapy (Lowe and Lin 2000). Bcl-2 protein is the first resistant factor identified 
acting against apoptosis. Subsequent studies have recognized many Bcl-2 protein 
homologues that are either pro- or anti-apoptotic. The interactions among these 
proteins could be the determining factor of cell death or survival (Gross et al. 1999; 
Reed 1998). 
A major checkpoint in the common portion of the cell death pathway is the 
ratio of pro-apoptotic (BAX) to anti-apoptotic (BCL-2) members. Downstream of 
this checkpoint is two major execution programs: the caspase pathway and 
mitochondria dysfunction. Figure 6.1 shows the schematic model of mammalian of 
cell death pathway. 
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Cell Death Signal 
，r 
Pro-apoptotic Anti-apoptotic  
Death Checkpoint  
，r 
Release of Cytochrome C  
from mitochondria  
y 
Caspase Activation 
Figure 6.1 Schematic model of mammalian cell death pathway. 
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Figure 6.2 shows the schematic model of cell cycle. Aside from the normal 
cell cycle, regulatory processes exist such as restriction point or START, and the 
blocks resulting from DNA damage. These control events were named checkpoints 
and have been reviewed frequently. DNA damage initially produces a checkpoint 
arrest that provides time for repair. But if repair is not soon completed, the cells 
retain the mutations or undergo apoptosis. G1 checkpoint genes, including p53, are 
involved in apoptosis. Wild-type p53 activates the Bax gene, which inhibits the 
ability of Bcl2 to protect cells against apoptosis. In addition, Bcl2 mRNA levels 
decline after p53 activation (O'Connor et al. 1997). Therefore, p53-dependent 
apoptosis may be caused by an increase in the ratio of BAX to BCL2. Different cells 
show various apoptotic responses. It remains unclear what makes one cell type 
become arrested in response to DNA damage, while another may apoptose. 
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Figure 6.2 Schematic model showing the four phases of the cell cycle. 
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6.2 RESULTS 
ER positive MCF-7 and ER negative MDA-MB-231 cell death assay 
Because baicalein exhibited the strongest antiestrogenic effect, the ability to 
induce cell death in ER-positive breast cancer cells were investigated Baicalein was 
indeed a more power death inducer to MCF-7 cells among various flavonoids tested 
as shown in Figure 6.4. Subsequently test on MDA-MB-231 illustrated that all 
flavonoids had the same strength of introducing cell death in ER-negative cells 
(figure 6.3). These differential effects on ER-positive and negative cells suggested 
that antiestrogenicity was, at least, a factor of death in ER-responsive cells. 
I l l 
Figure 6.3 Programmed cell death assay for MDA-MB-231 cells treated with 
various phytoestrogens. Cells were treated with quercetin, kaempferol, baicalein, 
genistein, flavone and biochaninA at concentrations of 0, 0.1, 1, 10，25 and 50 
|imol/L for 48 h. Values are means 士SEM, n=4. Means marked (*) significantly 
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Figure 6.4 Programmed cell death assay for MCF-7 cells treated with various 
phytoestrogens. Cells were treated with quercetin, kaempferol, baicalein, genistein, 
flavone and biochanin A at concentrations of 0，0.1, 1，10, 25 and 50 jiimol/L for 48 h. 
Values are means 士SEM, n=4. Means marked (*) significantly (户<0.05) differ from 
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Bcl-2, Bax and PS2 mRNA expression 
Because the ERE-driven luciferase activities were increased by genistein in 
the presence or absence of 17P-estradiol, the transcriptional activities of two estrogen 
responsive genes were investigated in MCF-7 cells. Compared to the control (0 
fimol/L genistein), the RT-PCR results indicated PS2 and Bcl-2 mRNA expressions 
were up-regulated by genistein at all concentrations tested represented by lanes 8 and 
9 in MCF-7 cells (Figure 6.5). 25 }imol/L gensitein at which apoptotic induction was 
observed also induced the expressions. PS2 and Bcl-2 have been widely accepted as 
estrogen responding genes. These results agreed to the ER transactivation data as 
presented in Chapter 5. Besides, the PS2 and Bcl-2 mRNA expressions were 
up-regulated by quercetin and kaempferol at all concentrations tested represented by 
lanes 2, 3, 4 and 5. And, there was no expression of PS2 mRNA expression detected 
in MDA-MB-231 cells. 
As the differential death caused by various phytoestrogens were seen in 
MCF-7 cells, the expressions of Bcl-2 and Bax were measured in these two cell lines. 
Since there are two functional ER responsive elements identified in Bcl-2, our 
hypothesis was that Bcl-2 should vary and be affected by the respective 
estrogenic/antiestrogenic properties of the phytoestrogens. Figure 6.5 illustrated that 
baicalein treatment represented by lanes 6 and 7 in MCF-7 cells did not illustrate any 
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increases in Bcl-2 expression, whereas other phytoestrogens did not enhance the 
expression. On the other hand, no differences in Bcl-2 expression were observed in 
MDA-MB-231 cells. Bax expressions were gradually increased as the phytoestrogen 
concentration rose, and the trend was the same for all phytoestrogens in either 
MCF-7 or MDA-MB-231 cells. 
Figure 6.6 illustrated an extra experiment to illustrate the dose-response of 
baicalein on Bcl-2, Bax and PS2 expressions; Figure 6.7 illustrate an extra 
experiment to illustrate the dose-response of genistein on Bcl-2, Bax and PS2 
expressions; Figure 6.8 illustrated an extra experiment on the dose-response of 
quercetin on Bcl-2, Bax and PS2 expressions. Figure 6.9 illustrated an extra 
experiment on the dose-response of kaempferol on Bcl-2, Bax and PS2 expressions. 
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Figure 6.5 Effects of phytoestrogens on the mRNA expression of Bcl-2 and Bax 
in MDA-MB-231 and MCF-7 cells. MCF-7 cells were treated with 10 and 25 
mmol/L quercetin, kaempferol, baicalein and genistein for 48 h. Messenger RNA 
was extracted from the cultures, and semi-quantitative RT-PCR reactions were 
performed. The PCR products were visualized by ethidium bromide staining. Lane 1 
is the control culture treated with the carrier solvent; lanes 2, 3 are cells treated with 
10 and 25 )Limol/L quercetin, respectively; lanes 4，5 are 10 and 25 jumol/L 
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Figure 6.6 Dose response Bcl-2 and Bax expression of baicalein on MCF-7 cells. 
Lane 1 is the control culture treated with the carrier solvent; lanes 2，3, 4, 5 and 6 are 
cells treated with 0.1, 1，5, 10 and 25 |imol/L baicalein respectively. 
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Figure 6.7 Dose response Bcl-2 and Bax expression of genistein on MCF-7 cells. 
Lane 1 is the control culture treated with the carrier solvent; lanes 2，3，4, 5 and 6 are 
cells treated with 0.1, 1, 5, 10 and 25 |amol/L genistein respectively. 
6 5 4 3 2 1 
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Figure 6.8 Dose response Bcl-2 and Bax expression of quercetin on MCF-7 cells. 
Lane 1 is the control culture treated with the carrier solvent; lanes 2, 3，4，5 and 6 are 
cells treated with 0.1, 1，5，10 and 25 ^mol/L quercetin respectively. 





Figure 6.9 Dose response Bcl-2 and Bax expression of kaempferol on MCF-7 
cells. Lane 1 is the control culture treated with the carrier solvent; lanes 2，3，4，5 and 
6 are cells treated with 0.1, 1，5，10 and 25 |Limol/L kaempferol respectively. 
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Arrest at sub G1 phase of MCF-7 by baicalein 
Cells treated with 10 or 25 |j,mol/L baicalein for two days were collected and 
used for flow cytometric studies. Figure 6.8 shows the distribution of the cells in the 
Go/Gi，S and G2M phases, respectively, of the cell cycle as a function of treatment. 
Baicalein treatment induced an accumulation of cells in the GQ/GI phase of the cell 
cycle, mainly evident at the highest dose, with parallel depletion of the percentage of 
cells in G2/M. 
Flow cytometric measurements demonstrated a sub-Gl peak occurred in cells 
treated with 10 |amol/L and 25 |Limol/L baicalein. This result confirmed that baicalein 
induced apoptosis in MCF-7 cells at the concentrations tested. 
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Figure 6.10 Flow cytometry analysis of MCF-7 cells treated with baicalein. 
MCF-7 cells were treated with baicalein at various concentrations 0，1，10 and 25 
jimol/L for 48 hours, and were trypsinized and analysed for apoptotsis by prodidium 
iodide staining as described in METHODS. The amounts of apoptotic cells were 
shown as the arrow-labeled sub G1 peak. 
125 
Baicalein 0 fil Baicalein I 本il 
S S 
% GO-G 1: 11.28 
%(,(>-(, I: 12,17 
i 、 %S 後 6 
L ir 
10° 101 10^  10� 10" 10^  10' 10= 
Baicalcin 1.0 ul , Baicalein 25 fjJ 
% GO-G 1: 60.65 CiO-G 丨•. 64.36 
A . ” %S: 27.52 Apoptotic cells �“ S 23 69 
Apoptotic cells �,“込M:丨,.84 %G2-M.n.們 
10« 1(V 10? 10' 10' 10-' 1CP 
126 
6.3 DISCUSSION 
Baicalein could cause a greater amount of cell death in an ER-positive breast 
cancer line MCF-7 than the other flavonoids, but the differential apoptotic effect was 
not seen in the ER-negative MDA-MB-231 breast cancer cells. The apoptotic index 
indicated that the strongest cell death inducing was baicalein > biochanin A> 
quercetin�flavonel> kaempferol > genistein in MCF-7cell line. 
Since the combined effect of Bcl-2 and Bax could be a determinant of cell 
death, the variations in the estrogen-responsive Bcl-2 expression might account for the 
potent death induction of baicalein on MCF-7 cells. These results demonstrated that 
baicalein was the most promising agent in the prevention and treatment of breast 
cancer among the tested phytoestrogens under the criteria examined in current study. 
Bcl-2 and Bax expressions are crucial factors in apoptosis, and could be 
representations of ER-dependent and -independent pathways. This study 
demonstrated that the antiapoptotic protein Bcl-2 was reduced by baicalein at about 10 
to 25 |LIM in Figure 6.1. Since two functional estrogen responsive elements (EREs) 
have been located on the promoter of Bcl-2 (Perillo et al. 2000)，the decrease could be 
a result of the antiestrogenic effect of the phytochemical. On the other hand, the 
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mechanism of cell death induced by flavonoids may go through several 
ER-independent pathways. Bax expression and Jun-terminus kinase activity are two 
such pathways that are upregulated in the apoptotic response of MCF-7 cells treated 
with genistein (Leung et al. 2000). 
Besides, starting from concentration 10 |amol/L baicalein, the cells stopped 
cycling in G1 and die through apoptosis. The apoptotic cells give rise to the 'sub-Gl' 
peak in the DNA histogram. 
In conclusion we identified baicalein, a natural occurring flavone, as a potent 
antiestrogen in the current study. Its capability of introducing apoptosis to ER-positive 
breast cancer cells was stronger than the other flavonoids, and could be an alternative 
for adjuvant therapy or preventive measure for breast cancer. 
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CHAPTER 7 BAICALEIN CAN REDUCE INTRACELLULAR 
CHOLESTEROL AND TRIGLYCERIDE 
7.1 INTRODUCTION 
Cardiovascular disease is the leading cause of death among postmenopausal women. 
There have been numerous reports over past decade about the effect of tamoxifen on serum 
lipids profiles. These showed an average decrease of 13 % in total cholesterol and an 
average decrease of 19 % in low-density lipoprotein (Yasuo et al. 2000). However, the 
action of tamoxifen on lipid metabolism is still not known. 
Baicalein and gensitein bind to the estrogen receptor with different affinity as 
discussed in Chapter 4 and 5. They are selective estrogen receptor modulators like 
tamoxifen that is used to treat and prevent osteoporosis in postmenopausal women. In the 
present study, the effects of baicalein and genistein on lipid metabolism compared with that 
of estradiol were investigated using HepG2 cell lines derived from human hepatoma cells. 
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7.2 RESULTS 
Baicalein has beneficial effect on lipid metabolism 
Baicalein reduced the total concentration of cholesterol in HepG2 cells at 
concentration ranging from 0.1 to 10 jimol/L as shown in Figure 7.1. However, 
P-estradiol and genistein increased and remained unchanged in the total 
concentration of cholesterol at same concentrations tested. 
Both P-estradiol and genistein increased 4-fold and 2-fold the total 
concentration of triglyceride in HepG2 cells at concentration ranging from 0.1 to 
10|imol/L as shown in Figure 7.2 while baicalein produced no changes in the total 
concentration of triglyceride at same concentrations tested. 
In the presence of oleic acid, both p-estradiol and genistein produced greater 
amount of total concentration of triglyceride in HepG2 cells at concentration ranging 
from 0.1 to 10 ^mol/L as shown in Figure 7.3 while baicalein produced no changes 
in the total concentration of triglyceride at same concentrations tested. 
Moreover, in the presence of VLDL baicalein did not increase the total 
concentration of triglyceride, whereas P-estradiol and genistein did at a concentration 
of 1 jimol/L as shown in Figure 7.4. 
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FigureT.l Total cholesterol concentration in HepG2 treated with estradiol, 
baicalein and genistein. HepG2 cells were seeded in 24-well culture plates. 
Phytoestrogens at 0, 0.1，1 and 10 ^itnol/L were administered. After 24 h of treatment, 
cells were prepared for measurement of total cholesterol concentration. Values are 














































































Figure7.2 Total triglyceride concentration in HepG2 treated with estradiol, 
genistein and baicalein. HepG2 cells were seeded in 24-well culture plates. 
Phytoestrogens at 0, 0.1，1 and 10 |imol/L were administered. After 24 h of treatment, 
cells were prepared for measurement of total triglyceride concentration. Values are 
































































































Figure7.3 Total triglyceride concentration in HepG2 treated with estradiol, 
genstein and baicalein in the presence of oleic acid. HepG2 cells were seeded in 
24-well culture plates. Phytoestrogens at 0，0.1, 1 and 10 |Limol/L were administered 
with medium with 18 )amol/L oleic acid. After 24 h of treatment, cells were prepared 
for measurement of total triglyceride concentration. Values are means 士SEM, n=3. 
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Figure7.4 Total triglyceride concentration in HepG2 treated with estradiol, 
genistein and bacicalein in the presence of VLDL. HepG2 cells were seeded in 
24-well culture plates. Phytoestrogens at 0，0.1, 1 and 10 |amol/L were administered 
with medium with 50 )ag/m VLDL. After 24 h of treatment, cells were prepared for 
measurement of total triglyceride concentration. Values are means 士SEM, n=3. 
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7 3 DISCUSSION 
With cardiovascular disease being a leading cause of death in postmenopausal 
women, the hypocholesterolemic effect of a soy-protein diet should be of benefit in 
counteracting the typical increase serum cholesterol associated with estrogen 
deficiency. Soy isoflavones may decrease risk for heart disease by lowering blood 
cholesterol levels. Recent studies show that soy isoflavones are responsible for the 
cholesterol-lowering effect, which some believe may be Soy protein has been shown 
partially due to the isoflavones associated with the proteins. 
Oleic acid and VLDL have been reported to increase triglycerides synthesis and 
the intracellular lipid content of HepG2 cells (Yasuo et al. 2000). In the present study, 
baicalein significantly reduced the intracellular cholesterol and triglyceride in the 
presence or absent of oleic and VLDL in HepG2 cells. However, genistein had not 
changed in the intracellular cholesterol concentration and increased the intracellular 
triglyceride concentration in the absent or presence of oleic acid and VLDL. 
Therefore, baicalein might potentially be a safer treatment in patients with 
unstable triglyceride levels or a history of hypertriglyceridemia. 
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CHAPTER 8 SUMMARY 
Menopause leads to many physiological changes in women, such as hot flashes, 
urogenital atrophy, and most importantly, osteoporosis. Recent practice is to dispense 
estrogen to post-menopausal women. However, this hormone replacement therapy 
(HRT) has negative impact on health. Both in vivo and in vitro studies have associated 
estrogens to increased incidences of breast (Colditz et al. 1999) and endometrial 
(Pickar et al. 1998) cancers. An isoform of estrogen receptor (ER) has been discovered 
amid this HRT dilemma. The two types of ER, now known as a and (3, have different 
specificity and tissue distribution (Kuiper et al. 1997). The differences offer an 
opportunity of developing specific estrogen receptor modulators (SERMs) targeting 
bone lost but not promoting cancers in the breast and endometrium (Dechering et al. 
2000). 
Many studies have illustrated that genistein can modulate the activity of 
estrogen by way of receptor binding. Because of the structural similarity to genistein, 
we hypothesized that some natural-occurring flavonoids could be a better SERM 
than genistein. 
In this study, baicalein was demonstrated to be the most potent antiestrogenic 
compound among the tested flavonoids. Baicalein at a considerably low dosage could 
suppress estradiol-induced transactivation in estrogen receptor (ER) alpha and beta. 
140 
This antiestrogenic effect could be explained partly by the fact that baicalein was a 
relative strong competitor to estradiol for receptor binding. Since Bcl-2 is an 
antiapoptotic protein that bears two functional estrogen responsive elements (ERE) in 
its promoter, its expression can be a factor of programmed cell death. In subsequent 
experiments, baicalein could reduce Bcl-2 mRNA expression, and the outcome could 
be the consequence of its antiestrogenic properties. Furthermore, baicalein did not 
induce a MCF-7 cell proliferation at low concentrations as the other flavonoids did. It 
could be the result of the reduced expression of Bcl-2. These results illustrated that 
baicalein suppressed Bcl-2 expression, and the mechanism could be related to its 
antiestrogenic activities. 
The differential actions of ERE transactivation and apoptosis of baicalein from 
other flavonoids tested may be related to their structural differences. The hydroxyl 
group at position R^ of baicalein as shown in Chapter 1 indicated the major difference 
in structure between them. 
In conclusion baicalein was identified, a natural occurring flavone, as a potent 
antiestrogen in current study. Cell death assay and flow cytometry analysis 
demonostrated that baicalein was a stronger apoptosis-inducing agent than the other 
flavonoids, and it has beneficial effects on lipid metabolism. It could be better 
natural alternative for estrogen responsive breast cancer treatment and prevention. 
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APPENDIX 1 ABBREVIATIONS 
Amp Ampicilin 
Bp Base Pair 
BSA Bovine Serum Albumin 
CDNA Complementary Deoxyribonucleic Acid 
dATP Deoxyadenosyl Triphosphate 
dCTP Deoxycytosinyl Triphosphate 
dGTP Deoxyguanosinyl Triphosphate 
DMSO Dimethyl Sulfoside 
DNA Deoxynucleic Acid 
dNTP Deoxyribonucleotide Triphosphate 
DTT Dithiothreitol 
dTTP Deoxythymidunyl Triphosphate 
E Estrogen 
E2 17p-estradiol 
E.coli Escherichea Coli 
ECso 50% effective Concentration 
EDTA Ethylenediaminetetraacetate 
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ER Estrogen Receptor 
EtOH Ethanol 
FACS Fluorescence Activated Cell Sorting 
FBS Fetal Bovine Serum 
FW Formula Weight 
HEPES N-2-hydroxy-ethyl-piperazine-N'-2-
Ethane-sulfonic acid 
I C 5 0 50% Inhibitory Concentration 
kb Kilo-base 
kDa Kilo-dalton 
LB Luria-Bertani Medium 
mRNA Messenger Ribonucleic Acid 
MTT 3-[4,5-Dimethylthiazol-2-yl]-2,5-Diphenyl 
Tetrazolium Bromide 
PBS Phosphate Buffered Saline 
PI Propidium Iodide 
RNA Ribonucleic Acid 
RNase Ribonuclease 
rpm Revolutions per Minute 
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RPMI1640 Medium Rosewell Park Memorial Institute Tissue 
Culture Medium 1640 
RT-PCR Reverse Transcription-Polymerase Chain 
Reaction 
SDS Sodium Dodecyl Sulfate 
Tris Trizma Base 
v/v Volume/ Volume 
w/v Weight/ Volume 
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APPENDIX 2 PRIMER LISTS 
The primers were illustrated below: 
Bcl2 Sense sequence: 5'-CGA CTT CGC CGA GAT GTC CAG CCA G- 3’ 
Anti-sense sequence: 5'-ACT TGT GGC CCA GAT AGG CAC CCA G- 3’ 
Bax Sense sequence: 5'-GCC CAT CTT CTT CCA GAT GGT GAG C-3' 
Anti-sense sequence: 5'- CAG CTC TGA GCA GAT CAT GAA GAC A-3' 
PS2 Sense sequence: 5'-ATG GCC ACC ATG GAG AAC A-3’ 
Anti-sense sequence: 5'-TCA GAG CAG TCA ATC TGT C-3 ’ 
Actin Sense sequence: 5'- GTG GGG CGC CCC AGG CAC CA-3’ 
Anti-sense sequence: 5'-CTC CTT AAT GTC ACG CAC GAT TCC-3' 
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APPENDIX 3 REAGENTS A N D BUFFERS 
Nucleic acid electrophoresis buffers 
TAE (Tris-acetate-EDTA), 50X stock solution 
242 g/L Tris base 
57.1 ml/L glacial acetic acid 
100 ml 0.5 M EDTA (pH 8.0) 
Stored at room temperature 
TBE (Tris-borate-EDTA), lOX stock solution 
108 g/L Tris base 
55 g boric acid 
40 ml 0.5 M EDTA, pH 8.0 
6X agarose fel loading buffer 
0.25 % (w/v) bromophenol blue 
40 % (w/v) sucrose 
60 mM EDTA (pH 8.0) 
Stored at 4 °C 
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Reagents for preparation of plasmid DNA 
PI: 50 mM Tris-HCl, pH8.0, 10 mM EDTA. Sterilized by autoclave for 15 minutes, 
then added RNase A to final concentration of 100 |ig/ml. Stored at 4 
P2: 0.2 M NaOH, 1 % SDS. Sterilized by autoclave for 15 minutes. 
P3: 3 M potassium acetate (pH 5.5). Sterilized by autoclave for 15 minutes. 
QBT: 50 mM MOPS, pH 7.0, 0.75 M NaCl，15 % isopropanol, 0.15 % Triton® 
X-100. Sterilized by filtration through 0.2 um filter. 
QC: 50 mM MOPS, pH 7.0, 1 M NaCl, 15 % isopropanol. Sterilized by filtration 
through 0.2 um filter. 
QF: 50 mM Tris-HCL, pH 8.5, 1.25 M NaCl, 15 % isopropanol. Sterilized by 
filtration through 0.2 um filter. 
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Medium for bacterial culture 
LB (Luria-Bertani) medium 
10 g/L bacto-tryptone 
5 g/L yeast extract 
lOg/LNaCl 
The solution was adjusted to pH 7.0 with NaOH and the volume was made up to 1 
liter with water. The medium was sterilized by autoclave. 
Medium for cell culture 
PBS (Dulbecco's Phosphate-Buffered Saline), lOX stock solution 
115 g/L Na2HP04 
39.6 g/L NaH2P04 
58.4 g/L NaCl 
pH was adjusted to 7.5 with HQ. It was sterilized by autoclave. 
Stored at 4 
RPMI 1640 Medium 
RPMI powder (for 1 liter) 
4.78 g/L HEPES 
159 
2g/LNaHC03 
The solution was adjusted to pH 7.2 with HCl and NaOH and the volume was made 
up to 1 liter with sterile water. It was then sterilized by filtration through (0.22|j,m) 
millipore filter. Stored at 4 
Reagent for flow cytometry analysis 
PI Propidium Iodide DNA Staining Solution 
The propidium iodide DNA staining solution was freshly prepared in PBS containing 
0.1% Triton X-100 (Sigma Chemical Co.), lOmM EDTA (pH7.4) (Sigma Chemical 
Co.), 50 |ig/ml propidium iodide (Sigma Chemical Co.) and 400 |ig/ml ribonuclease 
A (Rnase A) (Roche). The staining solution was pre-chilled at 4 °C before use. 
Reagent for MTT Assay 
MTT (3-[4, 5-Dimethylthiazol-2-yl]-2,5-Diphenyl Tetrazolium Bromide) 
MTT (Sigma Chemical Co.) was dissolved in PBS as 5 mg/ml stock solution and 
stored in dark at 4 °C. 
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